Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1529MR)

This product GTTS-WQ1529MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1529MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ361MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ12455MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ15388MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ14233MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ1365MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ14536MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ10123MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ14753MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW